Literature DB >> 3334410

Selection of a derivative of the antiviral agent 9-[(1,3-dihydroxy-2-propoxy)-methyl]guanine (DHPG) with improved oral absorption.

E J Benjamin1, B A Firestone, R Bergstrom, M Fass, I Massey, I Tsina, Y Y Lin.   

Abstract

Various diesters of 9-[(1,3-dihydroxy-2-propoxy)-methyl]guanine (DHPG) were screened in order to identify a derivative with improved oral absorption. The solubilities and dissolution rates decreased with increasing chain length and branching of the ester group. However, the dipropionate ester showed an anomalously faster dissolution rate. The rates of hydrolysis to DHPG in the presence of intestinal homogenates were found to increase with increasing carbon number for the straight-chain alkyl esters and decreased with branching. The shorter-chain alkyl esters were relatively more stable in intestinal homogenates than in liver homogenates. Therefore they may have a better membrane permeability than DHPG due to their intact ester group. The hydrolysis rates in human blood increased with increasing carbon number for the straight-chain alkyl esters. The dipropionate ester appeared to be the most promising derivative because of its rapid dissolution rate, slower hydrolysis in the intestine, and rapid conversion to DHPG in liver and blood.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3334410     DOI: 10.1023/a:1016462801968

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

1.  Rationale for design of biologically reversible drug derivatives: prodrugs.

Authors:  A A Sinkula; S H Yalkowsky
Journal:  J Pharm Sci       Date:  1975-02       Impact factor: 3.534

2.  Prodrugs of 9-(beta-D-arabinofuranosyl)adenine 2. Synthesis and evaluation of a number of 2',3'- and 3',5'-di-O-acyl derivatives.

Authors:  D C Baker; T H Haskell; S R Putt; B J Sloan
Journal:  J Med Chem       Date:  1979-03       Impact factor: 7.446

3.  Activity of esterase in the hydrolysis of 3',5'-diesters of 5-fluoro-2'-deoxyuridine in relation to the structure of the diester prodrugs.

Authors:  T Kawaguchi; Y Suzuki; Y Nakahara; N Nambu; T Nagai
Journal:  Chem Pharm Bull (Tokyo)       Date:  1985-01       Impact factor: 1.645

4.  Development of lipophilic prodrugs of mitomycin C. III. Physiochemical and biological properties of newly synthesized alkoxycarbonyl derivatives.

Authors:  H Sasaki; M Fukumoto; M Hashida; T Kimura; H Sezaki
Journal:  Chem Pharm Bull (Tokyo)       Date:  1983-11       Impact factor: 1.645

5.  Improved holder for intrinsic dissolution rate studies.

Authors:  J Wood; J Syarto; H Letterman
Journal:  J Pharm Sci       Date:  1965-07       Impact factor: 3.534

6.  Prodrugs of 9-beta-D-arabinofuranosyladenine. 1. Synthesis and evaluation of some 5'-(O-acyl) derivatives.

Authors:  D C Baker; T H Haskell; S R Putt
Journal:  J Med Chem       Date:  1978-12       Impact factor: 7.446

7.  A dual-column HPLC method for the simultaneous determination of DHPG (9-[(1,3-dihydroxy-2-propoxy)methyl]guanine) and its mono and diesters in biological samples.

Authors:  E J Benjamin; B A Firestone; J A Schneider
Journal:  J Chromatogr Sci       Date:  1985-04       Impact factor: 1.618

8.  Low-melting phenytoin prodrugs as alternative oral delivery modes for phenytoin: a model for other high-melting sparingly water-soluble drugs.

Authors:  Y Yamaoka; R D Roberts; V J Stella
Journal:  J Pharm Sci       Date:  1983-04       Impact factor: 3.534

9.  9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent.

Authors:  J C Martin; C A Dvorak; D F Smee; T R Matthews; J P Verheyden
Journal:  J Med Chem       Date:  1983-05       Impact factor: 7.446

10.  Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine.

Authors:  D F Smee; J C Martin; J P Verheyden; T R Matthews
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

View more
  6 in total

1.  Permeability characteristics of various intestinal regions of rabbit, dog, and monkey.

Authors:  N Jezyk; W Rubas; G M Grass
Journal:  Pharm Res       Date:  1992-12       Impact factor: 4.200

2.  Pharmacokinetic screening of o-naphthoquinone 5-lipoxygenase inhibitors.

Authors:  A Rakhit; S K Kuwahara; D R Jones; V F Soliman; A N Kotake; T D Oglesby; J W Wasley; S L Tripp; F L Douglas
Journal:  Pharm Res       Date:  1990-10       Impact factor: 4.200

3.  Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir].

Authors:  R A Vere Hodge; D Sutton; M R Boyd; M R Harnden; R L Jarvest
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

4.  Enhanced delivery of ganciclovir to the brain through the use of redox targeting.

Authors:  M E Brewster; K Raghavan; E Pop; N Bodor
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

5.  Chemical and enzymatic degradation of ganciclovir prodrugs: enhanced stability of the diadamantoate prodrug under acid conditions.

Authors:  M F Powell; A Magill; N Chu; K Hama; C I Mau; L Foster; R Bergstrom
Journal:  Pharm Res       Date:  1991-11       Impact factor: 4.200

Review 6.  Cyclodextrins in Antiviral Therapeutics and Vaccines.

Authors:  Susana Santos Braga; Jéssica S Barbosa; Nádia E Santos; Firas El-Saleh; Filipe A Almeida Paz
Journal:  Pharmaceutics       Date:  2021-03-19       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.